These study results are similar to prior studies that have assessed the effects of a DPP-4 inhibitor (alogliptin) added to pioglitazone and metformin combination therapy in patients with T2DM [19, 20]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.